Candid Capital Corporation

Candid Therapeutics is a clinical-stage biotechnology company focused on developing next-generation T-cell engagers (TCEs) for the treatment of autoimmune diseases. Launched in September 2024 with $370 million in capital, the company is led by Ken Song, the former CEO of RayzeBio. Candid's strategy involves depleting B-cells using multi-specific antibodies, a method that has shown promise in treating refractory autoimmune conditions. Its lead programs, CND-101 and CND-106, target CD20 and BCMA respectively, and were acquired through the simultaneous acquisitions of Vignette Bio and TRC 2004. The company aims to establish a leading position in the emerging field of immunology-oncology cross-over therapies.